» Articles » PMID: 28390905

Membrane-type Matrix Metalloproteases As Diverse Effectors of Cancer Progression

Overview
Publisher Elsevier
Date 2017 Apr 10
PMID 28390905
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Membrane-type matrix metalloproteases (MT-MMP) are pivotal regulators of cell invasion, growth and survival. Tethered to the cell membranes by a transmembrane domain or GPI-anchor, the six MT-MMPs can exert these functions via cell surface-associated extracellular matrix degradation or proteolytic protein processing, including shedding or release of signaling receptors, adhesion molecules, growth factors and other pericellular proteins. By interactions with signaling scaffold or cytoskeleton, the C-terminal cytoplasmic tail of the transmembrane MT-MMPs further extends their functionality to signaling or structural relay. MT-MMPs are differentially expressed in cancer. The most extensively studied MMP14/MT1-MMP is induced in various cancers along malignant transformation via pathways activated by mutations in tumor suppressors or proto-oncogenes and changes in tumor microenvironment including cellular heterogeneity, extracellular matrix composition, tissue oxygenation, and inflammation. Classically such induction involves transcriptional programs related to epithelial-to-mesenchymal transition. Besides inhibition by endogenous tissue inhibitors, MT-MMP activities are spatially and timely regulated at multiple levels by microtubular vesicular trafficking, dimerization/oligomerization, other interactions and localization in the actin-based invadosomes, in both tumor and the stroma. The functions of MT-MMPs are multifaceted within reciprocal cellular responses in the evolving tumor microenvironment, which poses the importance of these proteases beyond the central function as matrix scissors, and necessitates us to rethink MT-MMPs as dynamic signaling proteases of cancer. This article is part of a Special Issue entitled: Matrix Metalloproteinases edited by Rafael Fridman.

Citing Articles

SLC25A35 enhances fatty acid oxidation and mitochondrial biogenesis to promote the carcinogenesis and progression of hepatocellular carcinoma by upregulating PGC-1α.

Yu H, Bai L, Jin L, Zhang Y, Xi Z, Wang D Cell Commun Signal. 2025; 23(1):130.

PMID: 40065301 PMC: 11895242. DOI: 10.1186/s12964-025-02109-y.


The Anti-Metastatic Potential of Aronia Leaf Extracts on Colon Cancer Cells.

Owczarek K, Caban M, Sosnowska D, Kajszczak D, Lewandowska U Nutrients. 2024; 16(23).

PMID: 39683504 PMC: 11643985. DOI: 10.3390/nu16234110.


Long-Circulating and Targeted Liposomes Co-loading Cisplatin and Mifamurtide: Formulation and Delivery in Osteosarcoma Cells.

Li B, Zhao Q, Yang H, Wang X, Zhang Z, Gong Y AAPS PharmSciTech. 2024; 25(8):272.

PMID: 39592553 DOI: 10.1208/s12249-024-02992-7.


Identification and validation of matrix metalloproteinase hub genes as potential biomarkers for Skin Cutaneous Melanoma.

Zhang Z, Zhao M, Zhou Z, Ren X, He Y, Shen T Front Oncol. 2024; 14:1471267.

PMID: 39493455 PMC: 11527786. DOI: 10.3389/fonc.2024.1471267.


The mechanism of MMP14-positive tumor-associated fibroblast subsets in inhibiting PD-1 immunotherapy for esophageal cancer through exosomal tsRNA-10522.

Wang J, Zheng C, Lu J, Xu X, Xiang G, Li J Funct Integr Genomics. 2024; 24(5):186.

PMID: 39377944 PMC: 11461773. DOI: 10.1007/s10142-024-01447-3.